News Lilly throws lifeline to Sangamo with $1.4bn licensing deal A $1.4 billion gene therapy alliance with Eli Lilly has come at an opportune time for Sangamo as its cash reserves start to dry up.
News ACC25: Positive results with Lilly's Lp(a)-lowering drug Eli Lilly's lepodisiran has been shown to reduce Lp(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial.
News Lilly to appeal after CHMP rejects Alzheimer's drug Kisunla The CHMP has advised against EU approval of Eli Lilly's Alzheimer's drug Kisunla, potentially handing an advantage to Eisai/Biogen's rival drug.
News Novo Nordisk's CagriSema data disappoints investors again Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.
News Lilly uses Oscars ad to warn about 'untested' GLP-1s Eli Lilly has used an Oscars ad to urge people not to use unapproved and untested weight-loss medicines in a swipe at the compounding sector.
News Lilly unveils $27bn reshoring drive around four new plants Trump threatened tariffs if businesses do not reshore production to the US - and Lilly has now revealed a $27bn spend on new domestic facilities.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
